Sign In
Buy MKGAF
$149.28
-7.84 (-4.99%)
At Close: Jun 22, 2026
Merck KGaA says MS drug fails in late-stage trials
03:53pm, Tuesday, 05'th Dec 2023
Germany's Merck KGaA said on Tuesday the company's experimental multiple sclerosis drug evobrutinib did not meet the primary goal in highly anticipated late-stage trials.
Evotec: Attractive Spec 'Buy', But Merck KGaA Is Still Better
08:42pm, Sunday, 12'th Nov 2023
Evotec SE's appeal is based on its valuation and upside potential in the drug discovery and development sector. The company's financial performance is average, with negative margins and subpar busines
Merck KGaA Q3 earnings down 20% on weak biotech, electronics demand
01:03am, Thursday, 09'th Nov 2023
Germany's diversified group Merck KGaA reported a 20% decline in quarterly operating profit on weak demand for specialty materials that are used to make biotech drugs and semiconductors.
Merck KGaA: Company With A Potential Upside
04:47am, Wednesday, 01'st Nov 2023
Merck KGaA is an undervalued pharma company with a long history and strong fundamentals. The company has above-average margins and a diverse business portfolio in healthcare, life sciences, and electr
Merck KGaA widens work on 'DNA damage' drugs in deal with China's Hengrui
04:45am, Monday, 30'th Oct 2023
Germany's Merck KGaA on Monday said it struck a collaboration deal with Chinese drugmaker Jiangsu Hengrui Pharmaceuticals to widen Merck's work in an area known as "DNA damage response" drugs.
Merck KGaA says MS drug has blockbuster potential; key data expected in December
02:08am, Thursday, 19'th Oct 2023
The CEO of Germany's Merck KGaA said the company's experimental multiple sclerosis drug can be a "blockbuster", an industry term for annual sales that exceed $1 billion, even after concerns emerged th
Merck KGaA raises prospect of return to sales growth next year
02:03am, Thursday, 19'th Oct 2023
Germany's diversified group Merck KGaA has raised the prospect of returning to revenue growth next year, recovering from a slump in demand for its specialty materials to produce biotech drugs and semi
Exscientia stock surges on Merck KGaA partnership
09:13am, Wednesday, 20'th Sep 2023
Exscientia PLC shares climbed as much as 30% in pre-market trading on Wednesday after the precision-medicine company announced a new, multi-year collaboration with German science and technology compa
Merck KGaA: Expect A 10% CAGR EBITDA Increase In 2024-2025
11:40am, Sunday, 13'th Aug 2023
Merck KGaA reported disappointing Q2 results with a decrease in gross profit and EBIT compared to the previous year. The company remains confident in its 2025 targets despite reducing its full-year gu
Merck KGaA (MKGAF) Q2 2023 Earnings Call Transcript
07:21am, Saturday, 05'th Aug 2023
Merck KGaA (OTCPK:MKGAF) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belén Garijo - Chief Executive Officer Helene von
Strong start of the year in our health care department, says Merck KGaA CFO
09:44am, Thursday, 11'th May 2023
Marcus Kuhnert, CFO of Merck KGaA, discusses the company first-quarter results.
Ranking The Diversified Healthcare Giants
10:53pm, Sunday, 22'nd Jan 2023
The Top Six Healthcare Products and Service companies are some of the most popular investments in the market. However, they offer varying financial profiles.
Trim Big Pharma For Merck KgaA
03:39am, Wednesday, 04'th Jan 2023
Big pharma performed well in 2022, but the time to trim is drawing close. As a more diversified investment, I believe former parent company of Merck & Co, Merck KGaA offers a better long-term investme
MERCK Kommanditgesellschaft auf Aktien (MKGAF) CEO Belen Garijo on Q3 2022 Results - Earnings Call Transcript
04:03pm, Thursday, 10'th Nov 2022
MERCK Kommanditgesellschaft auf Aktien (OTCPK:MKGAF) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Constantin Fest - Head, IR Belen Garijo - Group, CEO Marcus Kuhn
Merck KGaA (MKGAF) CEO Belén Garijo on Q1 2022 Results - Earnings Call Transcript
10:38am, Friday, 13'th May 2022
Merck KGaA (OTCPK:MKGAF) Q1 2022 Earnings Conference Call May 12, 2022 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belén Garijo - CEO of the Group Marcus Kuhnert - CF
